Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) by 46.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,943 shares of the biopharmaceutical company’s stock after selling 91,900 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.05% of Arbutus Biopharma worth $340,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ABUS. Invesco Ltd. lifted its position in Arbutus Biopharma by 5.7% during the 4th quarter. Invesco Ltd. now owns 69,831 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 3,780 shares in the last quarter. Teacher Retirement System of Texas grew its position in Arbutus Biopharma by 18.7% in the fourth quarter. Teacher Retirement System of Texas now owns 42,144 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 6,644 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Arbutus Biopharma by 10.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,397 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 8,308 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Arbutus Biopharma by 18.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 56,452 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 8,648 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Arbutus Biopharma by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,222,201 shares of the biopharmaceutical company’s stock worth $3,997,000 after purchasing an additional 9,955 shares in the last quarter. Institutional investors and hedge funds own 43.79% of the company’s stock.

Arbutus Biopharma Trading Up 2.3%

ABUS stock opened at $3.58 on Friday. The firm has a 50 day simple moving average of $3.29 and a 200-day simple moving average of $3.33. The company has a market capitalization of $685.67 million, a P/E ratio of -8.33 and a beta of 1.23. Arbutus Biopharma Co. has a twelve month low of $2.71 and a twelve month high of $4.73.

Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings data on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.04). The company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $2.54 million. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. On average, research analysts predict that Arbutus Biopharma Co. will post -0.39 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ABUS shares. Chardan Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a report on Friday, March 28th. Wall Street Zen upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, March 29th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $5.50.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.